LP
RAPP

LMR Partners’s Rapport Therapeutics RAPP Stock Holding History

LMR Partners’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,000
Closed -$355K – 1679
2024
Q4 		$355K Hold
20,000
– – ﹤0.01% 880
2024
Q3 		$410K Sell
20,000
-30,000
-60% -$645K ﹤0.01% 866
2024
Q2 		$1.16M Buy
+50,000
New +$1.16M 0.01% 643

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LMR Partners's RAPP Position: Q1 2025 in Review

LMR Partners sold out of Rapport Therapeutics (RAPP) in Q1 2025, closing a stake of 20,000 shares — an estimated $355K sold.

LMR Partners first reported a position in RAPP in Q2 2024 and held it in 3 quarters. The position peaked at $1.16M in Q2 2024. 77 funds tracked by Wall St. Rank hold RAPP as of Q1 2025.

  • LMR Partners reported no remaining Rapport Therapeutics position as of Q1 2025 after selling out during the quarter.
  • LMR Partners sold 20,000 Rapport Therapeutics shares in Q1 2025, an estimated $355K.
  • LMR Partners first reported a position in Rapport Therapeutics in Q2 2024 and held it in 3 quarters.
  • LMR Partners's Rapport Therapeutics position peaked at $1.16M in Q2 2024.
  • 77 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.